GA-40 is a preparation based on plant peptides, the world’s first gene protector. GA-40 is derived from whorled Solomon’s-seal (Polygonatum verticillatum) and contains plant peptides of a molecular weight 15 to 98 kilodaltons. Under natural conditions, these peptides protect plants from damaging effects of infections, toxins, and ionizing radiation.

 Entering the human body, the peptides of GA-40 are able to protect the membrane and intracellular structures of normal cells – receptors regulated proteins, ligands and genes – from pathogenic viruses, bacterial toxins, and wave effects.

 But the main point is that plant peptides realize their inherent effects: react with cell membranes and interact with regulatory proteins. When the patient’s organism is weakened by chemotherapy or antibiotics, the peptides of GA-40, through the interaction with the membranes of lymphocytes and macrophages, enhance the activity of cellular immunity. GA-40 not only protects normal genes, but also contributes to the programmed death of malignant cells.

 The GA-40 gene protector has not only antitumor, but also anti-infective properties: it protects cells from the affections of viruses, prevents the reproduction of pathogenic bacteria, strengthen influence on the body by antibacterial and antiviral drugs.

Also, studies in 2019 showed that GA-40 helps cleanse the body of harmful toxins, has a pronounced detoxifying effect, including after heavy metal poisoning.

Yes, it is perfectly safe. GA-40 is a lyophilisate of plant peptides of small molecular weight, obtained from environmentally friendly plant raw material. Unlike animal-derived immunocorrectors, GA-40 has an unsurpassed safety profile because it does not contain large molecular weight polypeptides that can trigger allergic reactions and autoimmune inflammatory processes.

GA-40 is indicated for any diseases and conditions associated with disturbance of the full-fledged immune response of the human organism, including chronic infections and cancer.

Clinical data also indicate that the plant peptides contained in the GA-40 preparation can inhibit the penetration of viruses into healthy liver cells, as well as activate regulatory macrophages, which in turn synthesize anti-fibrotic enzymes. Thus, GA-40 is successfully used to treat hepatitis and cirrhosis.

Our research team works closely with the leading clinics and Research & Development Institutes of Georgia, the United States of America, Germany and Japan, which allows to conduct the nonclinical and clinical trials in accordance with the international GLP and GCP programs. In particular, nonclinical and clinical trials of GA-40 have been successfully completed under the international GLP and GCP programs at the following investigation sites: Laboratory of Biologically Active Substances and Molecular Biomedicine at the Department of Plant Physiology and Biotechnology, Tbilisi State University and with direct involvement of the Biomedical Research & Development Center of the Ministry of Health of Georgia; Research & Development Facilities of Otsuka Pharmaceutical Co., Ltd., Japan; Tokushima Cell Technology Institute, Japan; Department of Pathology, University of Washington, USA.

Yes, the experience with GA-40 has been accumulated for more than 20 years.  GA-40 has proved its efficacy in the combined treatment of melanoma, cervical cancer, breast cancer, leukemia and other cancers.

The GA-40 gene protector has confirmed its ability to program an atypical cell for natural death or apoptosis. Tumor tissue receives a double blow: on the one hand, peptides use additional resources of the immune system to fight against atypical cells; on the other hand, peptides independently integrate into cell metabolism, causing its apoptosis. This is confirmed by clinical experience.

Apoptosis is a natural programmed cell death. The mechanisms of apoptosis are triggered when biochemical processes are disturbed in a cell or signs of mutation appear. The use of GA-40 in patients with aggressive malignant neoplasms significantly improves the results of protocol treatment regimens.

The plant peptides of GA-40 are capable of reacting with both membrane and intracellular structures of hepatocytes. Peptides protect hepatic cells from the harmful actions of pathogenic viruses, prevent the virus integration into the nucleus of the hepatocyte, and also, due to the intracellular blockade of the TGF trigger protein, prevent the transformation of hepatocytes into fibrous fiber-producing cells. Thus, GA-40 prevents the onset of hepatic fibrosis.

Yes, the experience of GA-40 using indicates its high efficiency in preventing metastasis and recurrences. For example, the use of GA-40 in patients with aggressive malignant neoplasms significantly improves the results of protocol treatment regimens.